GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Palatin Technologies Inc (STU:PTN) » Definitions » Valuation Rank

Palatin Technologies (STU:PTN) Valuation Rank


View and export this data going back to 1993. Start your Free Trial

What is Palatin Technologies Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Palatin Technologies Valuation Rank Related Terms

Thank you for viewing the detailed overview of Palatin Technologies's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Palatin Technologies (STU:PTN) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Palatin Technologies Inc (STU:PTN) » Definitions » Valuation Rank
Comparable Companies
PLUR IGC PMN SRZN RNXT BOLT HRGN AURX IPA NKGN OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
PTN:USA PTN:Germany
Address
4B Cedar Brook Drive, Cranbury, NJ, USA, 08512
Website
https://www.palatin.com
Palatin Technologies Inc is a part of the healthcare sector. The company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its main product in clinical development is bremelanotide, which treats hypoactive sexual desire disorder, which is a type of female sexual dysfunction.